BOULDER, Colo., Sept. 25, 2015 /PRNewswire/ -- Array
BioPharma Inc. (Nasdaq: ARRY) will hold a conference call to
discuss preliminary results from two melanoma trials and a
colorectal cancer trial on Monday, September
28, 2015. Ron Squarer, Chief Executive Officer, and
Victor Sandor, M.D., Chief Medical
Officer, will lead the call.
The trials include a Phase 2 combination trial of binimetinib
and encorafenib in BRAF-mutant melanoma patients (LOGIC2), a Phase
1b/2 combination trial of binimetinib and a CDK4/6 inhibitor in
NRAS-mutant melanoma patients and a Phase 2 combination trial of
encorafenib and an EGFR inhibitor with or without the addition of a
PI3K inhibitor in patients with BRAF-mutant colorectal
cancer. Data from these trials will be presented at the
European Society of Medical Oncology's (ESMO) annual European
Cancer Conference (ECC) or were presented at the 2015 ESMO World
Congress of Gastrointestinal Cancer.
|
Conference Call
Information
|
|
Date:
|
Monday, September 28,
2015
|
|
Time:
|
9:00 a.m. eastern
time
|
|
Toll-Free:
|
(844)
464-3927
|
|
Toll:
|
(765)
507-2598
|
|
Pass
Code:
|
43837177
|
|
Webcast, including
Replay and Conference Call Slides:
http://edge.media-server.com/m/p/ky8z35w4/lan/en
|
About Array BioPharma
Array BioPharma Inc. is a
biopharmaceutical company focused on the discovery, development and
commercialization of targeted small molecule drugs to treat
patients afflicted with cancer. Six registration studies are
currently advancing related to three cancer drugs. These programs
include binimetinib (MEK162 / wholly-owned), encorafenib (LGX818 /
wholly-owned) and selumetinib (AstraZeneca). For more information
on Array, please go to www.arraybiopharma.com.
|
CONTACT:
|
Tricia
Haugeto
|
|
Array BioPharma
Inc.
|
|
(303)
386-1193
|
|
thaugeto@arraybiopharma.com
|
Logo -
http://photos.prnewswire.com/prnh/20121029/LA02195LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/array-biopharma-to-hold-conference-call-to-discuss-clinical-data-presentations-in-melanoma-and-colorectal-cancer-on-september-28-2015-300149033.html
SOURCE Array BioPharma